Verastem, Inc. Receives Orphan Drug Designation in the EU for VS-6063 in Mesothelioma

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Cambridge, MA - June 13, 2013 - Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for ... (more)

http://www.biospace.com/news_story.aspx?StoryID=299953&full=1